Amarin Corp Plc (AMRN)

[sstyles]

Vascepa 2.0--it's worth reviewing TerraPharma's tweet on this back in 2020. I wonder if this is the lifecycle mgmt product/drug that KM hinted at and others have surmised on this board.

🔥UPDATE🔥 Vascepa 2.0 candidate with partner Mochida (developer of Epadel) phase 2 was apparently a success as they have just announced a Phase 3 for the once daily, self emulsifying new epa formula product (MND-2119). $AMRNhttps://t.co/JtxpE8oUXV

— TerraPharma (@TerraPharma1) January 8, 2020

https://pj.jiho.jp/article/244669

from the patent: https://patents.justia.com/patent/10493052

Ethyl eicosapentaenoate ester (hereinafter abbreviated as EPA-E) is commercially sold as an oral therapeutic agent for ameliorating ulcer, pain, and coldness associated with arteriosclerosis obliterans as well as hyperlipidemia (product name Epadel, Mochida Pharmaceutical Co., Ltd.). When EPA-E is administered orally under fasting, increase in plasma EPA concentration is smaller than the case of the oral aminimistration after the meal conceivably because absorption of the EPA-E requires secretion of bile acid and food coponents as a carrier. Accordingly, Epadel is instructed to be orally administered three times a day each time immediately after the meal (see Non-Patent Literature 1).

However, dosage method or drug compliance has become a problem for those people not taking meals three times a day with the recent change in the life style, patients who can only take meals at a reduced amount, patients who can only take a fluid diet (milk, rice broth, starch gruel, egg, soup, juice, or oral nutritional supplement), patients with reduced absorption ability of the intestinal tract (for example, elderly, patients of intestinal disease, patients after intestinal surgery, terminal cancer patients, and patients taking a lipase inhibitor), or patients who are unable to take meals such as those after the cerebral infarction.


In addition, there has so far been no report of the preparation which is less affected by meals and which can be administered to a patient who is unable to take meals or which can be orally administered to a patient under fasting such as a patient before going to bed; a preparation which can rapidly increase blood ?3PUFA concentration by the administration under fasting such as administration before the meal or before going to bed and which can rapidly and effectively realize the intended pharmacological action, for example, suppression of the increase of the postprandial serum TG; an ?3PUFA preparation which can be encapsulated in a gelatin capsule or the like and which can be used at a reduced volume; or a preparation with no or reduced ethanol content that have solved the ethanol-related problems as described above.